Hello Cell & Gene Readers,
Are the methods used for developing the current generation of biopharmaceuticals, monoclonal antibodies, hormone replacements, etc., applicable to the next generation of biotech advanced therapy medicinal products (ATMPs)? When developing and manufacturing cell and gene therapies, do biopharma methods apply?
Patient advocacy plays a tremendously crucial role in the cell and gene sector. Jamie Ring, head of patient advocacy at Spark Therapeutics and a Cell & Gene Editorial Advisory Board member, shared with me valuable information about patient advocacy (e.g. what it is, what it’s not, and the difference between patient advocacy in healthcare overall versus patient advocacy in gene therapy), which we will cover in detail in the coming weeks. To start, Ring lists and explains the three pillars of patient advocacy.
Erin Harris, editor in chief
Follow me on Twitter